{"analyses":[{"ciLowerLimit":"0.056","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.332","estimateComment":"The HR and 95% CI were estimated from a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","pValueComment":"The 2-sided nominal p-value was calculated based on a stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.136","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval were not reached due to insufficient number of events at the time of data cutoff.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% confidence interval were not reached due to insufficient number of events at the time of data cutoff.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A - Pirtobrutinib"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","id":"OG001","title":"Arm B - Bendamustine Plus Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)","title":"Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Months"}